What We're Reading: Page 130
Industry reads hand-picked by our editors
Dec 20, 2021
Dec 17, 2021
-
The Wall Street Journal
Judge Throws Out Purdue Pharma’s Deal to Shield Sacklers From Opioid Lawsuits
-
FiercePharma
Novavax's COVID-19 vaccine scores WHO emergency listing, opening up supply to COVAX
-
The New York Times
F.D.A. Will Permanently Allow Abortion Pills by Mail
-
Reuters
AstraZeneca therapy works against Omicron; results mixed for Regeneron
Dec 16, 2021
-
NPR
Omicron evades Moderna vaccine too, study suggests, but boosters help
-
The Wall Street Journal
In a Bad Year for Biotech Stocks, Deals and Vaccines Were Winners
-
FierceBiotech
ALS drug discoverer Verge signs on Merck, Lilly for nearly $100M oversubscribed funding round
-
Reuters
Bristol Myers drug wins first U.S. approval for Graft versus Host Disease prevention
Dec 15, 2021
-
The Wall Street Journal
JPMorgan’s Big Healthcare Conference Goes Virtual on Omicron Concerns
-
POLITICO
Biden’s FDA pick on track for confirmation with GOP help
-
Bloomberg
Omicron Raises Stakes for Quick Covid Sequencing
Dec 14, 2021
-
The Washington Post
Democrats’ plan to cap insulin prices faces GOP threat, skeptical advocates
-
STAT
Moderna, Amgen among biotech heavyweights pulling out of JPM conference over Covid concerns
-
Nature
Antibody–oligonucleotide conjugates enter the clinic
-
The New York Times
Merck’s Covid Pill Might Pose Risks for Pregnant Women
Dec 13, 2021
-
The Wall Street Journal
The Big Vaccine Pivot: Merck Falters on Covid-19 Shots, Then Makes One for Rival J&J
-
The Boston Globe
‘This is confusing the hell out of us.’ No one knows how Omicron originated, but scientists have theories
-
STAT
Roche two-armed antibody posts strong tumor responses in lymphoma study, rivaling CAR-T therapy
-
Endpoints News
Eli Lilly's Van Naarden hands $380M cash to Flagship-backed upstart in major new oncology deal
Previous
